AZN Stock Analysis: Buy, Sell, or Hold?
AZN - AstraZeneca PLC
$164.50
-4.97 (-2.93%)
▼
5d:
-14.82%
30d:
-9.75%
90d:
-18.66%
HOLD
MODERATE Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Jul 27, 2026
12d
Get Alerted When AZN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called AZN this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: AZN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: AZN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$355.50
Based on 9.0% avg growth
INTRINSIC VALUE TODAY
$220.74
25.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: AZN is currently trading at $164.50, which is considered oversold relative to its 30-day fair value range of $174.69 to $189.19. From a valuation perspective, the stock is trading at a discount (Forward PE: 17.8) compared to its historical average (26.7). Remarkably, the market is currently pricing in an annual earnings decline of 12.7% over the next few years. This pessimistic expectation contrasts with the company's recent 5.3% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, AZN is in a downtrend. The price is currently testing key support at $164.45. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: AZN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $215.89 (+31.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AZN is in a downtrend. The price is currently testing key support at $164.45. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: AZN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $215.89 (+31.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$174.69 -
$189.19
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 31.2% below Wall St target ($215.89)
- CAUTION: 5-day price weakness (-14.8%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$174.69 -
$189.19
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$164.45
Resistance Level
$196.41
Current Trend
Downtrend
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
17.75
Wall Street Target
$215.89
(+31.2%)
Revenue Growth (YoY)
12.5%
Earnings Growth (YoY)
5.3%
Profit Margin
17.2%
Valuation Discount vs History
-12.7% cheaper
PE vs Historical
17.8 vs 26.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-12.7%
(market-implied from PE analysis)
1-Year Target
$148.05
(-10%)
2-Year Target
$133.25
(-19%)
3-Year Target
$119.92
(-27%)
3-Yr Target (if PE normalizes)
(PE: 18→27)
$180.37
(+10%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 14.0%)
$299.03
(+82%)
Base:
(SPY PE: 17.8, Growth: 14.0%)
$243.73
(+48%)
Bear:
(PE: 15.1, Growth: 14.0%)
$207.17
(+26%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (26x PE), but valuation improves significantly next year (18x PE) as earnings recover.
Trailing PE: 25.52 | Current EPS (TTM): $6.64
Bull Case
$260.16
(+58%)
Analyst growth 39.6%, PE expands to 28.1
Base Case
$236.51
(+44%)
Market implied 39.6%, PE stable at 25.5
Bear Case
$115.24
(-30%)
Severe decline -20.0%, PE contracts to 21.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 17.8 to 26.7
Stabilization Target:
$247.42
(+50.4%)
PE Expansion Potential:
+50.4%
Share & Embed Analysis
Last updated: July 14, 2026 6:40 PM ET
Data refreshes hourly during market hours. Next update: 7:40 PM
Data refreshes hourly during market hours. Next update: 7:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AZN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1240 | 56 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 65 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$263 | 58 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$223 | 59 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$356 | 56 HOLD |
